Mapakna Lp (Nifedipine)

Nifedipine blocks L‑type calcium channels in the smooth muscle of blood vessels and in cardiac tissue. This inhibition reduces calcium entry, preventing muscle contraction, which leads to vasodilation of arteries, lowered peripheral resistance, and decreased myocardial oxygen demand, thereby lowering blood pressure and easing angina.

The appropriate dose of Mapakna Lp is determined by the prescribing clinician based on the individual patient's condition, response, and tolerance. Dosage may vary for hypertension, angina, or Raynaud's phenomenon, and adjustments are made according to therapeutic goals and any observed side effects.

Safety of nifedipine in pregnancy and lactation has not been definitively established. It is generally classified as a drug of unknown risk, and clinicians usually avoid its use unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a healthcare professional is essential.

To request Mapakna Lp, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Mapakna Lp (nifedipine) is a dihydropyridine‑type calcium channel blocker, primarily causing arterial vasodilation. Compared with non‑dihydropidine agents such as verapamil or diltiazem, nifedipine has a stronger effect on peripheral vessels and less direct impact on cardiac conduction, making it especially useful for hypertension and angina.

Store Mapakna Lp at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity, which could affect tablet integrity and potency.

Mapakna Lp is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional. Dosing frequency and timing are prescribed by the treating physician based on the specific indication.

Serious risks include severe hypotension, which can cause fainting or shock, myocardial infarction in susceptible individuals, and rare but potentially life‑threatening allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience sudden weakness, chest pain, or signs of an allergic response.

Mapakna Lp should be avoided in patients with known hypersensitivity to nifedipine or any component of the formulation, in those with severe aortic stenosis, uncontrolled heart failure, or cardiogenic shock, and in individuals where the risks outweigh the benefits as assessed by their physician.